Showing 1 to 3 of 3 results


China Approves Novel Influenza Drug Onradivir
China approved Onradivir, a novel influenza A treatment targeting the PB2 protein, offering faster symptom relief and lower resistance potential than existing drugs like oseltamivir and baloxavir marboxil, potentially reducing the global burden of influenza.
China Approves Novel Influenza Drug Onradivir
China approved Onradivir, a novel influenza A treatment targeting the PB2 protein, offering faster symptom relief and lower resistance potential than existing drugs like oseltamivir and baloxavir marboxil, potentially reducing the global burden of influenza.
Progress
48% Bias Score


Baloxavir Shows Superior Efficacy Against Avian Influenza H5N1 in Mice
A study found baloxavir's superior efficacy against avian influenza H5N1 in mice compared to oseltamivir, except via contaminated milk, highlighting its potential role in pandemic preparedness due to different antiviral mechanisms and various infection routes.
Baloxavir Shows Superior Efficacy Against Avian Influenza H5N1 in Mice
A study found baloxavir's superior efficacy against avian influenza H5N1 in mice compared to oseltamivir, except via contaminated milk, highlighting its potential role in pandemic preparedness due to different antiviral mechanisms and various infection routes.
Progress
36% Bias Score

JAK Inhibitors Linked to Increased Viral Infection Risk
A new study by the Norwegian University of Science and Technology (NTNU) found that common anti-inflammatory drugs called JAK inhibitors can weaken the body's immune response to viruses like the flu and COVID-19, potentially causing severe infections; the research, published in NAR Molecular Medicin...

JAK Inhibitors Linked to Increased Viral Infection Risk
A new study by the Norwegian University of Science and Technology (NTNU) found that common anti-inflammatory drugs called JAK inhibitors can weaken the body's immune response to viruses like the flu and COVID-19, potentially causing severe infections; the research, published in NAR Molecular Medicin...
Progress
44% Bias Score
Showing 1 to 3 of 3 results